Scpharmaceuticals Performance
| SCPHDelisted Stock | USD 5.67 0.01 0.18% |
The entity has a beta of 0.36, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Scpharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Scpharmaceuticals is expected to be smaller as well. Scpharmaceuticals right now has a risk of 0.0%. Please validate Scpharmaceuticals semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Scpharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Scpharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Scpharmaceuticals is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 46.8 M | |
| Total Cashflows From Investing Activities | 29.3 M |
Scpharmaceuticals |
Scpharmaceuticals Relative Risk vs. Return Landscape
If you would invest 567.00 in Scpharmaceuticals on October 10, 2025 and sell it today you would earn a total of 0.00 from holding Scpharmaceuticals or generate 0.0% return on investment over 90 days. Scpharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Scpharmaceuticals, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scpharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scpharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scpharmaceuticals, and traders can use it to determine the average amount a Scpharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SCPH |
Based on monthly moving average Scpharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scpharmaceuticals by adding Scpharmaceuticals to a well-diversified portfolio.
Scpharmaceuticals Fundamentals Growth
Scpharmaceuticals Stock prices reflect investors' perceptions of the future prospects and financial health of Scpharmaceuticals, and Scpharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scpharmaceuticals Stock performance.
| Return On Equity | -9.34 | |||
| Return On Asset | -0.57 | |||
| Profit Margin | (1.84) % | |||
| Operating Margin | (0.89) % | |||
| Current Valuation | 315.46 M | |||
| Shares Outstanding | 53.68 M | |||
| Price To Book | 28.45 X | |||
| Price To Sales | 6.09 X | |||
| Revenue | 36.33 M | |||
| EBITDA | (77.43 M) | |||
| Cash And Equivalents | 55.85 M | |||
| Cash Per Share | 2.04 X | |||
| Total Debt | 52.69 M | |||
| Debt To Equity | 0.32 % | |||
| Book Value Per Share | (0.40) X | |||
| Cash Flow From Operations | (70.54 M) | |||
| Earnings Per Share | (1.81) X | |||
| Total Asset | 107.52 M | |||
| Retained Earnings | (366.49 M) | |||
About Scpharmaceuticals Performance
By evaluating Scpharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Scpharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Scpharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Scpharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts. SC Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.Things to note about Scpharmaceuticals performance evaluation
Checking the ongoing alerts about Scpharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scpharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scpharmaceuticals is not yet fully synchronised with the market data | |
| Scpharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 36.33 M. Net Loss for the year was (85.15 M) with profit before overhead, payroll, taxes, and interest of 34.21 M. | |
| Scpharmaceuticals currently holds about 55.85 M in cash with (70.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Over 80.0% of the company shares are owned by institutional investors |
- Analyzing Scpharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scpharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Scpharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scpharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scpharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scpharmaceuticals' stock. These opinions can provide insight into Scpharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Scpharmaceuticals Stock
If you are still planning to invest in Scpharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scpharmaceuticals' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |